Niacin
Alternative Names: KS 01016; Niaspan; Nicotinic acidLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Kos Pharmaceuticals
- Developer AbbVie
- Class Antihyperlipidaemics; Nicotinic acids; Peripheral vasodilators; Small molecules; Vitamins
- Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Lipid metabolism disorders
Most Recent Events
- 20 Sep 2013 First generic equivalent available in USA for Lipid disorders
- 25 Mar 2013 Adverse events data from the phase III AIM-HIGH trial in Lipid metabolism disorders released
- 15 Nov 2011 Final efficacy and adverse events data from the AIM-HIGH trial in Lipid metabolism disorders presented at the 84th Annual Scientific Sessions of the American Heart Association (AHA-2011)